An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.

The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.

The present invention relates to a Lactobacillus plantarum capsule and use thereof, and belongs to the technical field of microbe feed additives. The Lactobacillus plantarum capsule consists of a wall material, Lactobacillus plantarum, a cryoprotectant, stachyose, and Morchella esculenta zymolytic powders; wherein the wall material is composed of zymolytic soybean protein isolate, chitosan, xanthan gum, carrageenin, glycerin and trehalose, and when formulated into a mixed solution, the above substances have concentrations of 7 to 10% zymolytic soybean protein isolate, 1 to 2% chitosan, 1 to 3% xanthan gum, 0.1 to 0.5% carrageenin, 0.3 to 1% glycerin, and 0.5 to 2% trehalose. The Lactobacillus plantarum capsule of the present invention enhances resistance of the capsule to gastric acid, has very good enteric solubility, besides, it can effectively inhibit the growth of pathogenic germs to improve immunity, decrease incidence of diseases in livestock and poultry, and improve the breeding quality and benefit.

The present invention relates to a Lactobacillus plantarum capsule and use thereof, and belongs to the technical field of microbe feed additives. The Lactobacillus plantarum capsule consists of a wall material, Lactobacillus plantarum, a cryoprotectant, stachyose, and Morchella esculenta zymolytic powders; wherein the wall material is composed of zymolytic soybean protein isolate, chitosan, xanthan gum, carrageenin, glycerin and trehalose, and when formulated into a mixed solution, the above substances have concentrations of 7 to 10% zymolytic soybean protein isolate, 1 to 2% chitosan, 1 to 3% xanthan gum, 0.1 to 0.5% carrageenin, 0.3 to 1% glycerin, and 0.5 to 2% trehalose. The Lactobacillus plantarum capsule of the present invention enhances resistance of the capsule to gastric acid, has very good enteric solubility, besides, it can effectively inhibit the growth of pathogenic germs to improve immunity, decrease incidence of diseases in livestock and poultry, and improve the breeding quality and benefit.

Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

The present disclosure relates to a use of JULGI in diagnosing and treating guanine quadruplex-related disease and, more particularly, to a guanine-quadruplex (G-quadruplex) detecting composition comprising JULGI protein or a protein having a homology of 80% or higher to the JULGI protein, a diagnostic composition comprising the detecting composition, a diagnostic kit comprising the diagnostic composition, a method for providing information for diagnosis of a neurodegenerative disease, cancer, or a viral infection disease which are in pathological correlation with G-quadruplex, and a pharmaceutical composition for prevention or treatment of a neurodegenerative disease, cancer, or a viral infection disease, the pharmaceutical composition comprising JULGI protein, a protein having a homology of 80% or more with the JULGI protein, or a mutant protein thereof. Thanks to the activity of binding to the G-quadruplex structure, JULGI according to the present disclosure is expected to be advantageously used in diagnosing or treating various diseases that are in pathological correlation with the abnormal formation and dissociation of the G-quadruplex structure.

The present invention relates to compositions and methods for treating cancer. The invention makes use of peptides, nucleic acids encoding such peptides, and cells expressing such peptides, where the peptide comprises a tumor-associated carbohydrate antigen (TACA)-binding domain.

The present disclosure relates to a novel protein that specifically binds to a coronavirus, and a composition for neutralizing a coronavirus. A novel protein provided in the present disclosure is a novel protein in which virus binding ability is maintained but toxicity is eliminated on the basis of virus binding properties of bean-derived protein lectins, and thus can be used as a material for preventing the infection of a coronavirus or alleviating infectious diseases.

The present invention concerns certain peptides obtainable by hydrolysis from soy glycinin by the action of supernatant cultures of strains belonging to the genera Lactobacillus or Streptococcus. These peptides, extracts containing them and food products containing them are useful for the treatment and/or prevention of obesity and oxidative stress.

331 new found proteins in peanut with their sequence and the method of producing supplement including beverages on the basis of juice and powder from the peanut. 490 new found proteins in cashew sequence and method of producing food supplements including beverages on the basis of juice and powder from the cashew. 843 new found proteins in edamame (young soy) sequence and method of producing food supplement including beverages on the basis of juice and powder from the edamame (young soy)